Upperton Pharma Solutions is a UK-based contract development and manufacturing organisation (CDMO) that specialises in oral, nasal and pulmonary dosage forms. We offer a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical and commercial manufacture.
With more than 25 years of industry experience, Upperton excels in rapid product introductions, achieving the transition in as little as 4-6 weeks. Our project delivery is unparalleled and designed specifically to align with the values and innovation of small to mid-sized pharma companies. With subject matter experts and leadership team oversight on every project, you can trust our project delivery and expertise that covers all layers of our operations.
Our science-led approach drives two-way open dialogue and transparency. We have proven expertise in the development, scale-up, manufacturing and testing of oral, pulmonary and nasal drug products. For small molecules and biologics, our clinical manufacturing process trains support batch sizes from grams to kilograms.
Full-service contract development and manufacturing
Upperton’s science-led approach is supported by expertise at every stage of the development process. We offer services for formulation development, Phase I-III clinical supply, process scale-up and optimisation, registration activities, and analytical development and validation.
Our leadership team brings a wealth of experience in guiding products from initial development through to commercial production. The team’s commitment to quality and innovation has been recognised through numerous awards, such as the King’s Award for Enterprise 2023 and Pharma Industry Awards UK.
Upperton’s mission is to develop and manufacture high-quality drug products while fostering strong client relationships. We offer a variety of services, including formulation development, clinical supply from Phase I to Phase III, process scale-up, registration activities, and analytical development and validation.
Development, quality control and analytical capabilities
Upperton operates a state-of-the-art 50,000ft² development and manufacturing facility, Trent Gateway, in Nottingham, UK. Trent Gateway features ten individual good manufacturing practice (GMP) manufacturing suites, quality control laboratories, and dedicated spaces for analytical and formulation development. These facilities are equipped to process a variety of non-sterile dosage forms, including solids, liquids, semi-solids, and both nasal and inhaled products.
The Trent Gateway site supports a range of project requirements, from early formulation development to clinical trial supply and niche-scale commercial manufacturing. The research and development area spans 10,000ft², featuring laboratories for dosage form development, pilot plants for potent processing, and a dedicated analytical team.
The facility’s GMP manufacturing suites are designed to support oral, pulmonary, and nasal dosage forms, with capabilities for sterile processing and high-potency containment. Quality control is maintained through 8,000ft² of analytical laboratories, which are equipped with advanced technology for ensuring product quality.
Expertise in oral, nasal and pulmonary dosage forms
Upperton offers expertise in developing a range of small-molecule and biologic dosage forms, providing support from early feasibility studies through to clinical manufacture. We specialise in the development of both simple and complex oral dosage forms, including powders, capsules, and tablets. We can also produce IR, MR, SR and Minitabs tablets, as well as API, powder blend and lipid capsules.
Our UpperNose™ approach streamlines and accelerates the process of developing nasal dosage forms, making it more accessible to small and mid-sized innovators. UpperNose™ supports both liquid and dry powder formulations.
Upperton specialises in the development of pulmonary drug products through expertise in formulation development, particle engineering and device selection. We offer both dry powder and liquid formulation options, addressing factors such as solubility, stability, and target dose delivery.
Integrated CDMO services from preclinical to market stages
Upperton caters to an array of drug development needs, from preclinical stages through to late-phase development and commercial manufacturing. Our services are tailored to meet the unique challenges of each project and include feasibility studies to optimise spray-drying parameters, formulation development to ensure efficient API delivery, stability studies to verify storage conditions, and scale-up studies to prepare for GMP manufacturing.
Upperton’s analytical capabilities play a vital role in ensuring that products transition smoothly from development to clinical trials. Benefit from a science-led and structured approach that supports a seamless progression through the development pathway.
Science-led approach driving unparalleled project delivery
Upperton tailors projects to fit specific client timelines and requirements, prioritising effective communication and collaboration in project delivery. Each project is assigned a project manager who coordinates all activities and ensures that transparency is maintained through regular updates.
Project teams at Upperton are composed of experts from various disciplines, including development, GMP, analytical, quality analysis, and technical transfer. The inclusion of an Executive Leadership Team member in every project ensures that decisions are made under expert guidance.
